Remove FDA Approval Remove Marketing Remove Therapies
article thumbnail

Strengthening Warfighter Resiliency Using Broad-Spectrum or Host-Directed Therapies within the Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR) Program [Minireview]

ASPET

The CET RAIDR program conserves both time-to-market and funds by leveraging previous conventional development work as a launch point for repurposing efforts. CBRN MCMs). The CET RAIDR program currently focuses on strengthening collaborations with industry, academia, and other government partners to survey and test and evaluate (T&E) U.S.

Therapies 100
article thumbnail

FDA Approvals: Therapies for Lupus, MS, Cancer and a Genomic Alteration in Pigs

The Pharma Data

Food and Drug Administration (FDA) has approved belimumab (Benlysta®), the first-ever treatment for adults with lupus nephritis (LN) who are currently receiving standard therapy. We at the LRA are thrilled to share this news about belimumab and look forward to future approvals of other lupus nephritis treatment options.”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Roche receives FDA approval for first companion diagnostic to identify.

The Pharma Data

Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel, advancing the company’s commitment to personalised healthcare through tests that determine which patients are most likely to benefit from specific and targeted therapies. today announced U.S. A bout the VENTANA MMR RxDx Panel.

article thumbnail

Insights into cellular therapies for cancer treatment

Drug Target Review

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Regarding CAR-T cell therapy, could you highlight the promising findings that have been identified in the early stages of drug discovery, as well as potential challenges?

article thumbnail

Discover Strategies for Combatting Disruptions in Gene Therapy Development

Fierce BioTech

Discover Strategies for Combatting Disruptions in Gene Therapy Development Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1]

article thumbnail

Meaningful Moment for HIV Treatment as FDA Approves ViiV’s Monthly Shot

The Pharma Data

Food and Drug Administration (FDA) gave a greenlight for ViiV Healthcare ’s Cabenuva. Cabotegravir is a ViiV product marketed as Cabenuva, and rilpivirine is a Janssen product with a brand name Edurant. The once-a-month regimen was preferred by nine out of 10 patients over the daily oral therapy. clinical practices. “Not

article thumbnail

FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma

The Pharma Data

FDA Approves Danyelza (naxitamab-gqgk) for the Treatment of Neuroblastoma. This indication is approved under accelerated approval regulation based on overall response rate and duration of response. This indication is approved under accelerated approval based on overall response rate and duration of response.